Vision Mission & Strength
Quality Policy
Manufacturing Facility
R & D
Management Messages
Business Motto
Doxiva Montiva
Nixon Cefracef Bexen Fixpro Roxcef Roxcef injection Xinarox CV
Metavas MR Nitrogina SR
Tamino ER Tamino Plus
Vermikil
Florocin Toplevo 500 Revalon
Azaltic
Diazid Lijenta 5 Glucomin Lijenta-M Empa Diacana
Receca
Thixtra Anxionil Pandura Lyrinex
AMX Halopen
Flurodent
Mesala
Altrip
Nitide
Losarva Bisopress Adarbi Lovapres 5
Mecliz Plus Prokinet
Defungi Symbiotrin
Meroxin
Omecron Esotor Pansos Rablet Gastab
Arcet Fexten Itchlor Rupatid
Visnil
Isosal
Mucodil Nacsol Erdostin Broculyt
Irobest
Oxydrop
Flexivan ER Flexivan Nimovo Nipoxen Toralin Vurdon SR Etrib
Niprolac Oral Sol
Starcal D Nipro Gold Starcal M Vegecap-E Oxi-Q Polytamin V3N V4Z Starcal D Forte Starcal
Avator Rovator
Reflexen
Cialix Danafil
Japan Bangladesh joint venture company- NIPRO JMI Pharma held its annual sales conference 2018 at International Convention City, Bashundhara, Dhaka.....
Md. Mizanur Rahman, Chief Executive Officer (CEO) of NIPRO JMI Pharma Limited, has received a prestigious award as the best pharmaceutical professional in Bangladesh-2018.
Prescribing Information
Rupatadine is a long-acting, non-sedative antagonist of histamine H1-receptors. It also, antagonizes the platelet-activating factor (PAF). Both histamine and PAF causes bronchoconstriction and lead to an increase in the vascular permeability, acting as a mediator in the inflammatory process. This double mechanism of action gives Rupatadine a major clinical efficacy regarding agents that show an isolated antihistamine action. Rupatadine possesses other anti-allergic properties such as the inhibition of the degranulation of mast cells induced by immunological and non-immunological stimuli, and inhibition of the release of cytokines, particularly of the TNFa in human mast cells and monocytes.